tbuckley/cabot-search huggingface dataset:
Histone deacetylase 2 overexpression and Wnt/β-catenin signaling are distinct oncogenic event in human hepatocelluar carcinoma
Authors: Ji Heon Noh, Jaehwi Song, Jung Woo Eun, Hong Sug Kim, Su Young Kim, Won Sang Park, Nam Jin Yoo, Jung Young Lee, Suk Woo Nam
Journal: Cancer Research (2005)

2754  Colorectal cancer (CRC) and hepatocellular carcinoma (HCC) are one of the most common malignancies worldwide, and prognosis of advanced CRC and HCC remains very poor. Hence, discovery of target molecules for development of novel anti-cancer drugs is essential for improving prognosis of CRCs and HCCs. We previously analyzed expression profiles of CRCs and HCCs by means of a cDNA microarray representing 23,040 genes, and identified SMYD3, a human gene whose expression was significantly up-regulated in cancer tissues compared with corresponding non-cancerous colon or liver tissues. The predicted amino acid sequence of SMYD3 contained a zinc finger domain and a SET domain. Multiple tissue northern blot analysis revealed its abundant expression in the testis and skeletal muscle but not in other tissues examined. We further carried out colony formation assay and observed growth promoting effect of SMYD3 in NIH3T3 cells. Consistently, growth of CRC and HCC cells were suppressed by treatment with specific siRNA to this gene. SMYD3 protein was shown to associate directly with an RNA helicase, HELZ, to form a complex with RNA polymerase II, and to bind to “5’-CCCTCC-3’” segments in the promoter region of various genes. Moreover, a SET domain of this protein revealed histone H3-lysine 4 (H3-K4)-specific methyltransferase activity, which was enhanced in the presence of 90-kD heat shock protein (HSP90A). Further investigation using cDNA microarray identified a set of genes regulated by SMYD3, which included oncogenes, homeobox genes, and genes associated with cell cycle regulation. We searched for putative SMYD3-binding sequence in the 5’ flanking region of Nkx2.8, one of the most up-regulated genes by SMYD3, and found two putative binding sequences, between -510 bp and -467 bp. Reporter assay using plasmids containing the wild type binding sequences showed significantly elevated reporter activity compared to plasmid containing mutant binding sequences in SNU475 cells. In addition, gel retardation assay and chromatin immunoprecipitation assay uncovered that SMYD3 binds to the binding sequences in vitro and in vivo. These findings suggest that SMYD3 stimulates oncogenic activities by transcriptional regulation mechanisms, and inhibition of this transcriptional activity could be a promising strategy for treatment of CRC and HCC.
PTU-069 How many hours do stable coeliac patients take up in gastroenterology out-patient clinics?
Authors: M Yalchin, R Eckersley, T Coysh, J Cunningham, S Mann
Journal: Gut (2017)

Introduction  Patients with coeliac disease (CD) are usually stable clinically and biochemically at their annual review. Due to pressures on out-patient services we reviewed data to assess which patients actually require specialist gastrointestinal (GI) input, and raise the question as to who should see CD patients in clinics.  Method  Barnet Hospital is a District Hospital serving a population of 5 00 000 just outside North West London. This was a single centre, retrospective study of confirmed CD patients, under the care of three different gastroenterologists. Data was obtained from each consultant from their database. We reviewed the electronic records relating to each patient‘s last three clinic appointments, and assessed whether or not they were stable clinically and biochemically. We excluded patients with other significant GI co-morbidities and those who were newly diagnosed within the last two years.  Results  There were 192 patients with CD of whom, 160 fulfilled the inclusion criteria (F=107;67%). In each of the last 3 clinic reviews, 83% (n=133) were stable.  Only 17% (n=27) required GI input, including 18% (n=7) due to poor adherence to a gluten free diet, 28% (n=11) due to GI symptoms, 18% (n=7) due to weight loss, 18% (n=7) due to anaemia, 8% (n=3) due to elevated TTG and 10% (n=4) other.  Annual reviews by a gastroenterologist occurred in 83% (n=133). Dieticians saw patients less than once per year in 62.5% (n=100) of cases, and 37.5% (n=60) were actually never referred to a dietician.  Conclusion  BSG guidelines recommend that patients with CD are seen annually by a dietician and/or clinician for a clinical review, biochemical checks and for dietary adherence and advice 1 . NICE guidelines also state that patients should be seen annually for clinical review, height and weights check, bloods and to assess the need for nutritional advice 2 .  We have demonstrated that in a hospital that does not have a dietician led coeliac service, gastroenterologists typically see straight forward and stable patients annually 83% of the time. Assuming a 10 min follow-up slot, this equates to 22 hours per annum of specialist time, equivalent to 6.3 clinics each year.  Given the need to access our services for urgent referrals or unwell patients with other conditions, this study forms the basis for a business case to set up a dietician led coeliac service, with access to gastroenterologists only where needed.  References  . Coeliac disease: recognition, assessment and management. NICE guideline [NG20]. Sept 2015  . Ludvigsson JF, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut2014;63:1210–28.  Disclosure of Interest  None Declared
生分解性足場は急性脊髄損傷を有するヒト以外の霊長類における組織リモデリングと機能改善を促進する【Powered by NICT】
Authors: R Slotkin Jonathan, D Pritchard Christopher, Luque Brian, Ye Janice, T Layer Richard, S Lawrence Mathew, M O’Shea Timothy, R Roy Roland, Zhong Hui, Vollenweider Isabel, Edgerton V. Reggie, Courtine Gregoire, J Woodard Eric, Langer Robert
Journal: Biomaterials (2017)
Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United States
Authors: Neehar D. Parikh, Wesley J. Marrero, Jingyuan Wang, Justin Steuer, Elliot B. Tapper, Monica Konerman, Amit G. Singal, David W. Hutton, Eunshin Byon, Mariel S. Lavieri
Journal: Hepatology (2017)

Nonalcoholic steatohepatitis (NASH) cirrhosis is the fastest growing indication for liver transplantation (LT) in the United States. We aimed to determine the temporal trend behind the rise in obesity and NASH‐related additions to the LT waitlist in the United States and make projections for future NASH burden on the LT waitlist. We used data from the Organ Procurement and Transplantation Network database from 2000 to 2014 to obtain the number of NASH‐related LT waitlist additions. The obese population in the United States from 2000 to 2014 was estimated using data from the U.S. Census Bureau and the National Health and Nutrition Examination Survey. Based on obesity trends, we established a time lag between obesity prevalence and NASH‐related waitlist additions. We used data from the U.S. Census Bureau on population projections from 2016 to 2030 to forecast obesity estimates and NASH‐related LT waitlist additions. From 2000 to 2014, the proportion of obese individuals significantly increased 44.9% and the number of NASH‐related annual waitlist additions increased from 391 to 1,605. Increase in obesity prevalence was strongly associated with LT waitlist additions 9 years later in derivation and validation cohorts (R 2 = 0.9). Based on these data, annual NASH‐related waitlist additions are anticipated to increase by 55.4% (1,354‐2,104) between 2016 and 2030. There is significant regional variation in obesity rates and in the anticipated increase in NASH‐related waitlist additions ( P &lt; 0.01). Conclusion : We project a marked increase in demand for LT for NASH given population obesity trends. Continued public health efforts to curb obesity prevalence are needed to reduce the projected future burden of NASH. (H epatology 2017).
Abstract #5463: Fully human anti-phosphatidylserine antibody inhibits the growth of prostate cancer in mice
Authors: Yi Yin, Anita Kavlie, Philip Thorpe
Journal: Cancer Research (2009)

Phosphatidylserine (PS), a phospholipid normally residing in the inside leaflet of the plasma membrane, becomes exposed on tumor vascular endothelial cells in response to oxidative stresses in the tumor microenvironment. Anti-PS antibodies have been developed. Binding of anti-PS antibodies on the tumor endothelial cells recruits immune cells to destroy tumor vasculature. The antibodies also enhance anti-tumor immunity by blocking the immunosuppressive action of PS. A chimeric anti-PS antibody, bavituximab, is being used in combination with chemotherapy to treat patients with metastatic breast cancer in Phase II trials. We developed the fully human anti-PS antibody 1N11. Being fully human, 1N11 is less likely to evoke an anti-antibody response in clinic. The antibody was tested for cross reactivity profiles by ELISA, and its ability to localize to tumor vessels by immunofluoresence staining. 1N11 binds to PS through beta-2-glycoprotein 1 (\#946;2GP1) in the same manner as bavituximab. It recognizes human and mouse \#946;2GP1 with equal affinity, whereas bavituximab is selective for human \#946;2GP1. 1N11 localized specifically to tumor vascular endothelium after injection into severe combined immunodeficient mice bearing LNCaP and PC3 tumors. Treatment with castration increased the percentage of tumor vessels with 1N11 binding from 20% to 80% in mice bearing LNCaP xenografts. Treatment with docetaxel increased the localization of 1N11 on tumor vessels from 30 to 65% in mice bearing PC3 xenografts. To evaluate therapeutic efficacy of 1N11, we created a mouse IgG2a chimeric version, called mch1N11, to ensure compatibility with mouse effector cells and complement. Treatment with mch1N11 retarded the growth of orthotopic PC3 tumors by more than 90% as judged by bioluminescent imaging. Toxicity to the mice was not observed. These results provide the rationale for using 1N11 alone, or in combination with androgen deprivation therapy or chemotherapy to treat prostate cancer patients.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5463.
Functional and Prognostic Insights into the Altered Cancer Genome
Authors: Jinqiu Zhang, Xuejing Liu, Arpita Datta, Bing Lim, Krishna Karuturi, Patrick Tan, Philippe Broet, Sophie Broet, Lance Miller
Journal: Clinical Cancer Research (2007)

PL07-04   Copy number alterations (CNAs) that modify tumor behavior are frequently observed in cancer, yet the cancer-relevant genes they harbor remain largely undiscovered. Using modern microarray technologies, we are assessing the functional dynamics of genes and genomes towards a more holistic view of the mechanistic and prognostic underpinnings of the altered cancer genome. In this presentation, I will describe two emerging strategies we are exploring: one that seeks to pinpoint and functionally characterize oncogenes located at sites of recurrent amplification (in breast cancer), and another that seeks to harness the prognostic power of CNA-related genes in predicting patient outcomes (in non-small cell lung cancer).
同所性in vivoプラットフォームにおける骨膜組織工学【Powered by NICT】
Authors: J G Baldwin, F Wagner, L C Martine, B M Holzapfel, C Theodoropoulos, O Bas, F M Savi, C Werner, E M De-Juan-Pardo, D W Hutmacher
Journal: Biomaterials (2017)
Comment on Timmers et al. Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2016;39:2211–2217
Authors: Miriam Méndez-del Villar, Manuel González-Ortiz, Esperanza Martínez-Abundis, Karina G. Pérez-Rubio
Journal: Diabetes Care (2017)

The recent study by Timmers et al. (1) is a valuable randomized, double-blind, crossover clinical trial involving patients with well-controlled type 2 diabetes who were assigned to receive placebo and 150 mg/day resveratrol for 30 days to evaluate insulin sensitivity via hyperinsulinemic-euglycemic clamp. After the intervention, the authors found that hepatic and peripheral insulin sensitivity were not affected by the resveratrol treatment, and additionally, no significant changes in intrahepatic lipid content were found. However, the authors found an increase in intramyocellular lipid content in type 2 muscle fibers, a tendency for blood pressure to decrease, and an improvement of ex vivo mitochondrial function. The authors concluded …
Acute Neck Swelling and Chest Pain After Forceful Coughing
Authors: Roberto J. Vidri, Thomas Ng
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Facial Erosive Pustular Dermatosis After Cosmetic Resurfacing
Authors: Julie E. Mervak, Stephanie D. Gan, Emily H. Smith, Frank Wang
Journal: JAMA Dermatology (2017)

<h3>Importance</h3> Erosive pustular dermatosis (EPD) is a rare condition that typically affects actinically damaged skin of the scalp. Characterized by sterile pustules, erosions, and crusts, EPD is difficult to treat and heals slowly. The exact cause of EPD is unknown, although trauma is an inciting factor. <h3>Objective</h3> To describe 3 women who presented with prolonged facial erosions after cosmetic resurfacing procedures, specifically fully ablative carbon dioxide laser or medium-depth chemical peel. <h3>Design, Setting, and Participants</h3> This case series describes the clinical features, histopathological findings, laboratory results, and treatment of 3 patients with an ultimate diagnosis most consistent with facial EPD. Patients were evaluated between September 10, 2010, and May 6, 2016, in a dermatology clinic in an academic medical center. The patients were 3 women seeking diagnostic evaluation and therapeutic options for nonhealing facial erosions occurring after ablative procedures (carbon dioxide laser resurfacing or Jessner solution/trichloroacetic acid chemical peel). <h3>Main Outcomes and Measures</h3> Histologic examination and wound culture from initial presentation as well as clinical follow-up documenting improvement with therapeutic interventions. <h3>Results</h3> All 3 patients were women in their 50s or 60s for whom EPD was deemed to be the best diagnosis, after infection, immunobullous disorders, and other pustular dermatoses were considered. Histologic features were nonspecific. Treatment included a combination of topical and systemic therapies, such as corticosteroids, dapsone, isotretinoin, and/or antibiotics. Watchful waiting (tincture of time) appeared to be central to the healing process. <h3>Conclusions and Relevance</h3> After cosmetic resurfacing, patients may develop EPD isolated to the face. As a diagnosis of exclusion that should be considered in patients who have nonhealing wounds following ablative procedures, EPD is challenging to treat and may require the use of anti-inflammatory agents. Recognizing this condition is important, especially as cosmetic procedures become more widespread.
Cis and trans determinants of epigenetic silencing by Polycomb repressive complex 2 in Arabidopsis
Authors: Jun Xiao, Run Jin, Xiang Yu, Max Shen, John D Wagner, Armaan Pai, Claire Song, Michael Zhuang, Samantha Klasfeld, Chongsheng He, Alexandre M Santos, Chris Helliwell, Jose L Pruneda-Paz, Steve A Kay, Xiaowei Lin, Sujuan Cui, Meilin Fernandez Garcia, Oliver Clarenz, Justin Goodrich, Xiaoyu Zhang, Ryan S Austin, Roberto Bonasio, Doris Wagner
Journal: Nature Genetics (2017)
Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s
Authors: Patricia Garvey, Niamh Murphy, Paula Flanagan, Aline Brennan, Garry Courtney, Orla Crosbie, John Crowe, John Hegarty, John Lee, Margaret McIver, Carol McNulty, Frank Murray, Niamh Nolan, Cliona O'Farrelly, Stephen Stewart, Michele Tait, Suzanne Norris, Lelia Thornton
Journal: Journal of Hepatology (2017)
Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans
Authors: Robin Padickakudy, David Pereyra, Florian Offensperger, Philipp Jonas, Lukas Oehlberger, Christian Schwarz, Stefanie Haegele, Alice Assinger, Christine Brostjan, Thomas Gruenberger, Patrick Starlinger
Journal: Journal of Hepatology (2017)
TGF-β–induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche
Authors: Takashi Yahata, Abd Aziz Ibrahim, Yukari Muguruma, Mesut Eren, Alexander M. Shaffer, Nobuo Watanabe, Satoko Kaneko, Tetsuo Nakabayashi, Takashi Dan, Noriaki Hirayama, Douglas E. Vaughan, Toshio Miyata, Kiyoshi Ando
Journal: Blood (2017)
Contraceptive pill is linked to lower risk of rheumatoid arthritis, study finds
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Taking oral contraceptives is linked to a lower risk of developing rheumatoid arthritis, particularly in women who take the pill for seven or more consecutive years, research has shown.

But the study,1 published online in the Annals of the Rheumatic Diseases , did not find a significant link between breast feeding and a lower risk of developing rheumatoid arthritis, after accounting for various potentially influential factors.

Researchers in Sweden examined the possible link between developing rheumatoid arthritis—which is two to three times more common in women than in …
Genome-wide RNAi profiling to determine contexts of vulnerability in cancer cells
Authors: Gopinath Ganji, Quick Que, Holly Yin, Yue Li, Erica Bean, Wu Song, Mahesh Kumar, Yang Xiang, Jagatheswari Virayah, David Azorsa, Michael Barrett, Jeff Kiefer, Kerry Blanchard, Greg Tucker-Kellogg, Spyro Mousses
Journal: Clinical Cancer Research (2007)

C53   RNA interference has emerged as a powerful functional genomics technology to perform targeted gene knockdowns and study loss-of-function phenotypes. This has been exploited in various drug discovery and development applications, including target characterization and validation. The availability of reagent libraries has paved the way for genome-wide high throughput screens that have been recently reported by several groups. Here, we report a genome-wide loss-of-function siRNA screen of druggable targets (~7000 genes) in 4 cell lines representing different tumor types and genetic backgrounds. Assay development, validation, primary and confirmation screens were all done using a cell viability readout. Statistical approaches along with integrative analyses of orthogonal datasets (arrayCGH, mutation, expression) were employed to identify ‘essential’ or ‘survival’ genes that upon knockdown caused significant loss of viability in a general or cell-specific context. Wherever possible, genomics data from primary tumor samples has been leveraged to establish clinical relevance. A few examples will be shown and discussed. These ‘contexts of vulnerability/lethality’ provide valuable data in understanding target or pathway dependence and functional consequences. Pending further follow up, these findings are likely to shed light on new targets as well as the development strategy for targeted agents.
Case 64-1963
Authors: Grantley W. Taylor, Benjamin Castleman
Journal: New England Journal of Medicine (1963)

Presentation of CaseA seventy-seven-year-old woman entered the hospital because of nonunion of a fracture of the left femur.Twenty-one years previously the patient sustained a fracture of the left femur, which was treated with internal fixation and a cast for six months. The fracture healed satisfactorily, and she could walk without discomfort until ten years before admission, when pain in the left thigh developed. With the help of a cane she was able to walk with a limp despite moderate pain until five months before admission, when she slipped while getting out of a chair and fell to the . . .
酸化グラフェンへの応答に関与する長鎖非コードRNAのゲノムワイド同定と機能解析【Powered by NICT】
Authors: Wu Qiuli, Zhou Xuefeng, Han Xiaoxiao, Zhuo Yizhou, Zhu Siting, Zhao Yunli, Wang Dayong
Journal: Biomaterials (2016)
Abstract 16939: Reversible Myocardial Ischemia Sufficient to Produce Transient Stunning Leads to Delayed Cardiac Troponin I Release That Reflects Focal Myocyte Apoptosis in the Absence of Pathological Infarction
Authors: Brian R Weil, Rebeccah F Young, Xiaomeng Shen, Gen Suzuki, Jun Qu, John M Canty
Journal: Circulation (2015)

Introduction: The release of cardiac troponin I (cTnI) after reversible ischemia is controversial. It has been hypothesized that elevations in serum cTnI in this scenario reflect selective release from an exchangeable pool rather than cellular necrosis since irreversible injury with sarcolemmal membrane disruption does not begin until ischemia exceeds 15 minutes following a total coronary occlusion. Objective: To determine whether cTnI release occurs after a brief coronary occlusion when the duration of ischemia is insufficient to induce myocyte necrosis. Methods: Closed-chest propofol-anesthetized swine (n=10) were subjected to a 10 minute LAD occlusion. Blood sampling was performed to measure serum cTnI concentrations before, during and after ischemia. Myocardial tissue was collected either 1 hour (n=5) or 24 hours (n=5) after reperfusion for pathological assessment of infarction (TTC) and apoptosis (TUNEL). Results: Regional LAD wall thickening was 60 ± 4% at baseline and became dyskinetic during coronary occlusion (-4 ± 2%, p&lt;0.05). One hour after reperfusion, wall thickening improved but remained depressed relative to baseline, indicative of myocardial stunning (37 ± 4%, p&lt;0.05). It returned to normal after 24 hours (59 ± 2%). Serum cTnI was 0.01 ± 0.01 ng/mL at baseline and remained unchanged at the end of ischemia. A slight increase in cTnI was observed 1 hour after reperfusion (0.06 ± 0.02 ng/mL, p&lt;0.05 vs. baseline), followed by a marked elevation at 24 hours (1.02 ± 0.57 ng/mL, p&lt;0.05 vs. baseline). TTC staining demonstrated no evidence of infarction. Heart tissue collected 1 hour after reperfusion demonstrated a regional increase in apoptotic myocytes (LAD: 17.7 ± 3.7 myocytes/cm 2 vs. Remote: 3.1 ± 2.0 myocytes/cm 2 , p&lt;0.05). Myocyte apoptosis normalized 24 hours after reperfusion (LAD: 5.2 ± 2.3 myocytes/cm 2 vs. Remote: 3.6 ± 1.5 myocytes/cm 2 ) when serum cTnI remained elevated. Conclusion: A duration of reversible ischemia compatible with angina can lead to cTnI release that is similar in magnitude to that occurring with myocardial infarction. Rather than infarction or release from an exchangeable cTnI pool, the rise in serum cTnI is delayed and appears to reflect focal programmed myocyte death from apoptosis rather than myocardial necrosis.